Analysis of QTc duration alone (≥430 ms) yielded 72% sensitivity and 86% specificity for identifying LQTS mutation carriers, outperforming the sensitivity of Schwartz and Keating criteria.
Observational (n=513)
Do clinical diagnostic criteria (Schwartz, Keating) or QTc duration alone accurately predict inherited long QT syndrome mutation carriership compared to DNA testing in relatives of LQTS probands?
Analysis of QTc duration alone (≥430 ms) offers superior sensitivity compared to traditional Schwartz or Keating criteria for screening LQTS carriership in relatives of probands, though genetic testing remains the definitive standard.
AIMS: Previously published diagnostic systems, based on ECG analysis and clinical parameters (Schwartz criteria and Keating criteria), have been used to estimate the probability of inherited long QT syndrome (LQTS). Nowadays, a certain diagnosis can often be made by DNA testing. We aimed to establish the predictive power of the Schwartz and Keating criteria, using DNA testing as a reference, and to determine the best diagnostic strategy. METHODS AND RESULTS: We studied 513 relatives (aged >10 years) of 77 consecutive LQTS probands with a known disease-causing mutation. The Schwartz criteria identified 'high probability of LQTS' (score >or=4) in 41 of 208 mutation carriers, yielding 19% sensitivity and 99% specificity. The Keating criteria had 36% sensitivity and 99% specificity. Alternatively, by analysing QTc duration alone, we found that 430 ms is the optimal cut-off value to distinguish carriers (>or=430 ms) from non-carriers (or= 430 ms) as its sensitivity is far superior, although its specificity remains acceptable. In genotyped families, genetic testing is the preferred diagnostic test.
Hofman et al. (Wed,) conducted a observational in congenital long QT syndrome (n=513). Clinical diagnostic criteria (Schwartz and Keating) and QTc duration vs. DNA testing was evaluated on Identification of LQTS mutation carriers. Analysis of QTc duration alone (≥430 ms) yielded 72% sensitivity and 86% specificity for identifying LQTS mutation carriers, outperforming the sensitivity of Schwartz and Keating criteria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: